NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 6 நாட்களுக்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Anuh Pharma H1 FY27 PAT Jumps 42% to Rs 22.64 Cr; Tarapur Capacity Reaches 2,975 MTPA
Anuh Pharma released its H1 FY27 investor presentation, reporting a 1.8% YoY uptick in operating revenue to Rs 379.05 crore, while net profit rose 42.25% YoY to Rs 22.64 crore as the company prioritized high-margin products over volume. EBITDA margins expanded 261 bps to 9.74%, supported by a 15.3% increase in production to 987 MT. Crucially, the company inaugurated its new multi-purpose Tarapur Unit F-10 on October 20, 2026, adding 575 MTPA to expand overall capacity to 2,975 MTPA. Management anticipates delivering a 15-20% annual growth rate going forward as it ramps up exports from the new facility.
உச்சம் நம்பிக்கை
என்ன மாறியதுAnuh Pharma commissioned its new multi-purpose API unit F-10 at Tarapur on October 20, 2026, taking total capacity from 2,400 MTPA to 2,975 MTPA.
ஏன் இது முக்கியம்The expanded capacity gives head-room to scale higher-margin regulated market exports and supports management's targeted 15-20% annual growth trajectory.
📅 குறுகிய காலம்Positive sentiment driven by strong margin expansion in H1 and operationalization of the new Tarapur manufacturing block.
📈 நீண்ட காலம்Structural tailwinds depend on successful commercialization and regulatory approvals from regulated markets for products manufactured at the new F-10 facility.
⚠ அபாய எச்சரிக்கைகள்
Export dependency and customer concentration (Top 5 customers account for 36% of sales in H1 FY27)
API commodity price volatility and pricing pressure from competitors
👀 கவனிக்க வேண்டியவை
Track the utilization and export ramp-up of the newly commissioned 575 MTPA Tarapur Unit F-10 over H2 FY27, along with gross margin sustainability in upcoming quarterly results.
Q2 FY27 Net Profit Rises 47.3% YoY to ₹11.21 Cr; Revenue Flat at ₹185.24 Cr
Anuh Pharma reported a 47.3% YoY growth in Profit After Tax (PAT) to ₹1,121.31 lakhs (₹11.21 Cr) for the quarter ended September 30, 2026, compared to ₹761.25 lakhs in the previous corresponding period. Revenue from operations remained flat at ₹18,524.14 lakhs (₹185.24 Cr) versus ₹18,588.27 lakhs in Q2 FY26. EBITDA margin improved significantly to 9.47% from 6.92% a year ago, driven by better cost management and inventory adjustments. For the half-year (H1 FY27), PAT grew 42.3% YoY to ₹2,263.80 lakhs.
உச்சம் நம்பிக்கை
என்ன மாறியதுAnuh Pharma declared its unaudited financial results for the quarter and half-year ended September 30, 2026.
ஏன் இது முக்கியம்Demonstrates operating margin resilience and strong cash flow recovery despite stagnant top-line revenue in a commoditised bulk drug market.
📅 குறுகிய காலம்Profitability beat on margins is likely to be viewed positively in the near term, though flat revenue growth may keep sharp upside in check.
📈 நீண்ட காலம்Growth hinges on capacity utilization from its 1,500 MTPA plant, geographic expansion into regulated markets, and diversification away from commoditised macrolides.
⚠ அபாய எச்சரிக்கைகள்
Short-term debt increased to ₹19.48 Cr from zero in March 2026
Pricing power remains limited due to commoditised bulk drug competition
Revenue growth was flat YoY (-0.3%)
👀 கவனிக்க வேண்டியவை
Track whether API top-line volume growth revives in H2 FY27, along with the sustainability of operating margins above 9% amidst raw material price fluctuations.
Anuh Pharma Takes Possession of Vanquest Pharma's Tarapur Manufacturing Unit
Anuh Pharma Limited has received possession of a manufacturing facility from M/s. Vanquest Pharma Private Limited located at Tarapur, Boisar, Maharashtra. This handover follows the Asset Transfer Agreement executed on October 16, 2026. The company noted that there are no material changes from the previous terms disclosed, though financial deal consideration was not specified in this document. The acquisition adds physical manufacturing assets to support the company's existing bulk drugs and API operations.
நடுத்தரம் நம்பிக்கை
என்ன மாறியதுAnuh Pharma took physical possession of the Tarapur manufacturing facility under the Asset Transfer Agreement executed on October 16, 2026.
ஏன் இது முக்கியம்Adds manufacturing infrastructure in Maharashtra, potentially expanding production capacity beyond its current 1,500 MTPA base to support API growth.
📅 குறுகிய காலம்Operational handover is complete; near-term focus will be on regulatory clearances and modifications needed before commercial production begins.
📈 நீண்ட காலம்Could enhance long-term API output and market share if integrated effectively, supplementing current capacity expansion plans.
⚠ அபாய எச்சரிக்கைகள்
Facility modification and regulatory validation timelines could delay commercial output
Transaction consideration and financial impact details not disclosed in this update
👀 கவனிக்க வேண்டியவை
Track subsequent disclosures on operational integration timelines, required regulatory approvals (e.g., GMP certifications), and capex/capacity additions related to this facility.
Anuh Pharma to Acquire API Facility for ₹72.90 Cr, Adding 525 MTPA Capacity
Anuh Pharma Limited has signed an Asset Transfer Agreement to acquire the manufacturing facility of Vanquest Pharma Private Limited in Tarapur, Maharashtra, for a cash consideration of ₹72.90 crore. The acquired assets (land, building, plant, and machinery) will add 525 MTPA of capacity for APIs and intermediates, representing a 35% expansion over its current 1,500 MTPA base. The transaction value represents approximately 20.7% of the company's net worth (₹352 crore). The counterparty is an unrelated entity, and no equity shares are being issued.
உச்சம் நம்பிக்கை
என்ன மாறியதுAnuh Pharma has formally executed an Asset Transfer Agreement to purchase an API manufacturing plant from Vanquest Pharma for ₹72.90 crore.
ஏன் இது முக்கியம்The acquisition expands Anuh Pharma's API capacity by 35% (adding 525 MTPA to its 1,500 MTPA footprint), supporting volume growth and diversification beyond macrolides.
Asset Purchase Value: Rs. 72.90 CroreCapacity Addition: 525 MTPAAcquisition vs Net Worth: ~20.7%Capacity Growth vs Current (1,500 MTPA): +35.0%
📅 குறுகிய காலம்Positive sentiment driven by a sizeable inorganic capacity expansion funded without equity dilution.
📈 நீண்ட காலம்Expands long-term API and intermediate production volumes significantly, aiding geographic expansion and product diversification away from core macrolides.
⚠ அபாய எச்சரிக்கைகள்
Integration risk and regulatory compliance ramp-up before the new site can export to regulated markets
Cash outflow of ₹72.90 crore in an API environment with volatile raw material prices
👀 கவனிக்க வேண்டியவை
Track the completion timeline for the asset transfer and subsequent regulatory inspection approvals (WHO GMP/EDQM) needed to commercialize the 525 MTPA facility.
Anuh Pharma Approves Capex and ₹75 Cr Loan for Capacity Expansion
Anuh Pharma's Board of Directors has approved an investment in manufacturing assets to expand its production capacity. To fund the purchase of these assets, the board approved availing a loan of up to ₹75 crore, subject to terms, conditions, and regulatory approvals. Against the company's current net worth of ₹352 crore, the proposed debt facility represents ~21.3% of net worth for a currently debt-free entity. Detailed capacity addition metrics and execution schedules are yet to be disclosed.
உச்சம் நம்பிக்கை
என்ன மாறியதுBoard approved new capex into manufacturing assets and authorised borrowing up to ₹75 crore to fund the expansion.
ஏன் இது முக்கியம்The company is debt-free with 1,500 MTPA capacity; adding ₹75 crore in debt-funded assets indicates a significant scale-up to support target volume growth and regulated market expansion.
Approved loan limit: up to ₹ 75 crsLoan vs Net worth: ~21.3%Current debt: Rs 0 கோடிMeeting conclusion time: 04:35 p.m.
📅 குறுகிய காலம்Positive sentiment from expansion plans, though markets will wait for concrete capex size, product mix, and commissioning schedule.
📈 நீண்ட காலம்If successfully executed, the new capacity should drive revenue beyond the existing 1,500 MTPA base, aiding target growth of >20% in regulated markets.
⚠ அபாய எச்சரிக்கைகள்
Execution and commissioning delays
Re-leveraging a debt-free balance sheet with up to ₹75 crore debt
👀 கவனிக்க வேண்டியவை
Track subsequent SEBI LODR disclosures regarding specific capacity additions (in MTPA), capex completion timeline, product lines targeted, and final loan interest terms.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Anuh Pharma Q1 FY27 PAT Up 37.6% YoY to ₹11.42 Cr, EBITDA Jumps 41.6% to ₹19.36 Cr
Anuh Pharma released its Q1 FY27 investor presentation, reporting a 3.93% YoY growth in operating revenue to ₹193.81 crore. Operating profitability saw significant expansion, with EBITDA rising 41.56% YoY to ₹19.36 crore and EBITDA margins improving from 7.34% to 9.99%. Profit After Tax (PAT) grew 37.63% YoY to ₹11.42 crore, driven by a richer product mix and higher throughput from regulated markets. Production volume increased 19.46% YoY to 491 MT, with ROCE improving by 326 bps to 19.18%.
உச்சம் நம்பிக்கை
என்ன மாறியதுAnuh Pharma published its Q1 FY27 investor presentation outlining financial metrics, product/geographic mix, and pipeline development.
ஏன் இது முக்கியம்Demonstrates operating leverage and margin recovery from a higher-margin product mix and USFDA/EU GMP regulated market ramp-ups across its 2,400 MTPA facility.
📅 குறுகிய காலம்The strong YoY operational margin expansion to 9.99% is likely to be viewed constructively by market participants.
📈 நீண்ட காலம்Long-term growth remains tied to capacity utilisation of the 2,400 MTPA facility, penetration in regulated markets, and successful commercialisation of high-value new APIs.
⚠ அபாய எச்சரிக்கைகள்
Raw material price volatility affecting commodity API realisations
Customer concentration with top 5 customers accounting for 34% of sales in Q1 FY27
👀 கவனிக்க வேண்டியவை
Track the commercialisation timeline of new pipeline APIs (Pretomanid, Vonoprazan Fumarate) and regulatory clearance ramp-up across regulated export markets in subsequent quarterly disclosures.
37.6% YoY PAT Growth in Q1 FY27; EBITDA Margins Expand to 9.99%
Anuh Pharma reported a steady Q1 FY27 with revenue from operations growing 3.9% YoY to ₹193.81 Cr. The company saw a significant expansion in profitability, with Net Profit (PAT) rising 37.6% YoY to ₹11.42 Cr, driven by improved operational efficiency as EBITDA margins rose from 7.34% to 9.99%. While YoY performance is strong, revenue saw a marginal 4.1% sequential (QoQ) decline from ₹202.12 Cr. The company maintains a robust balance sheet with zero debt and a net worth of ₹352 Cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுAnuh Pharma released its Q1 FY27 financial results, showing a significant jump in profitability and margin expansion despite modest revenue growth.
ஏன் இது முக்கியம்The margin expansion suggests better cost management or a shift toward higher-margin products, which is critical for a medium-sized player in the competitive API industry.
📅 குறுகிய காலம்The stock may see positive sentiment in the short term due to the strong bottom-line growth and margin improvement exceeding revenue growth.
📈 நீண்ட காலம்Long-term value depends on the successful diversification beyond core macrolides and increasing the share of revenue from regulated markets like Western Europe and Mexico.
⚠ அபாய எச்சரிக்கைகள்
Raw material price volatility
Intense price-based competition in commoditized APIs
Regulatory compliance risks for exports to regulated markets
👀 கவனிக்க வேண்டியவை
Watch for the continued ramp-up of the 1,500 MTPA capacity and the company's ability to maintain margins amidst raw material price volatility in the commoditized API segment.
Anuh Pharma FY26 Revenue Up 15.7% to ₹776 Cr; USFDA Inspection Passed with Zero Observations
Anuh Pharma Limited reported a 15.66% YoY growth in annual revenue to ₹776 Cr for FY26, supported by a 25% increase in production volumes. Despite the top-line growth, the company faced margin pressure, with PAT declining 13.32% YoY to ₹41.05 Cr and EBITDA margins contracting to 8.56% from 10.64%. A significant positive is the successful completion of USFDA and EU GMP inspections in May 2026 with zero Form 483 observations, paving the way for further expansion into regulated markets.
முக்கிய அம்சங்கள்
Annual revenue grew 15.66% to ₹776 Cr, while Q4 FY26 revenue remained flat at ₹201 Cr.Successfully cleared USFDA and EU GMP inspections in May 2026 with zero Form 483 observations.Total production volume surged 24.99% YoY to 1,733 MT, reflecting high plant utilization.Net Profit (PAT) for FY26 fell to ₹41.05 Cr from ₹47.35 Cr in the previous year due to margin compression.Manufacturing capacity was expanded to 2,400 MTPA in 2025, up from 2,200 MTPA.
👀 கவனிக்க வேண்டியவை
Investors should weigh the strong regulatory compliance and volume growth against the declining profit margins. While the USFDA clearance is a long-term positive for market access, the immediate focus should be on the company's ability to recover profitability in a high-volume, low-margin environment.
Anuh Pharma reported a 16.6% YoY increase in FY26 revenue to ₹77,165.74 Lakhs, though annual PAT fell 13.3% to ₹4,104.61 Lakhs. For Q4 FY26, revenue was ₹20,211.72 Lakhs with a PAT of ₹1,168.14 Lakhs, showing a slight decline in profitability compared to the previous year. The company recommended a final dividend of ₹1.50 per share and is processing a promoter re-classification request for 0.95% of equity. EBITDA margins for the year compressed to 8.56% from 10.64% in FY25.
முக்கிய அம்சங்கள்
FY26 Revenue increased to ₹77,165.74 Lakhs from ₹66,151.49 Lakhs in FY25.FY26 PAT declined to ₹4,104.61 Lakhs vs ₹4,735.19 Lakhs, impacted by higher material costs.Board recommended a final dividend of ₹1.50 per share (30% of face value).EBITDA margin for FY26 stood at 8.56% compared to 10.64% in the previous fiscal.Nine promoter group entities holding 0.95% stake sought re-classification to the public category.
👀 கவனிக்க வேண்டியவை
While revenue growth is healthy, the margin contraction and PAT decline are concerns; investors should monitor management commentary on cost pressures. The ₹1.50 dividend offers some yield support for long-term holders.
Anuh Pharma Receives WHO Prequalification for Amodiaquine Hydrochloride API
Anuh Pharma Limited has successfully secured World Health Organization (WHO) Prequalification for its Amodiaquine Hydrochloride USP, a key anti-malarial Active Pharmaceutical Ingredient (API). This approval allows the company to supply the API to international markets, specifically targeting WHO-procured and donor-funded programs. Amodiaquine is a critical component in combination therapies for treating malaria, and this certification enhances the company's global competitiveness. The milestone is expected to strengthen Anuh Pharma's position as a preferred supplier for large-scale global health initiatives.
முக்கிய அம்சங்கள்
Received WHO Prequalification (WHO PQ) for Amodiaquine Hydrochloride USP API.Enables access to international donor-funded and WHO-procured procurement programs.Product is an essential medicine used in combination therapies for Plasmodium falciparum malaria.Strengthens the company's standing as a preferred global supplier in the anti-malarial segment.
👀 கவனிக்க வேண்டியவை
Investors should view this as a significant regulatory win that opens high-volume export opportunities; monitor for upcoming supply contracts and volume growth in the API segment.
Anuh Pharma Facilities Found Compliant in EDQM Audit
Anuh Pharma Limited has successfully completed an audit by the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its manufacturing facilities in Tarapur, Maharashtra. The audit covered units E-17/3, E-17/4, and E-18, all of which were found to be compliant with global quality standards. This successful inspection is a significant milestone as it ensures the company's continued access to European markets for its pharmaceutical products. The compliance reaffirms the company's commitment to high regulatory standards, potentially boosting investor confidence in its export capabilities.
முக்கிய அம்சங்கள்
EDQM audit successfully completed for three manufacturing units in Tarapur, Maharashtra.Facilities E-17/3, E-17/4, and E-18 were found fully compliant with European quality standards.The successful inspection reaffirms the company's adherence to global regulatory benchmarks.Ensures uninterrupted access to the European market for the company's pharmaceutical products.
👀 கவனிக்க வேண்டியவை
This regulatory clearance reduces operational risk and strengthens the company's export profile. Investors can maintain their positions as this secures a key revenue stream from the European region.
Anuh Pharma reported a robust Q3 FY26 with revenue at ₹201 Cr and a significant sequential recovery in EBITDA margins to 10.60%. A major highlight is the successful USFDA inspection in February 2026 with zero Form 483 observations, strengthening its position in regulated markets. While 9M FY26 PAT is down 15.85% YoY to ₹29.36 Cr, the quarterly performance shows strong momentum with PAT rising 76.7% QoQ. The company has also expanded its production capacity to 2,400 MTPA to meet growing demand.
முக்கிய அம்சங்கள்
9M FY26 Revenue increased 22.9% YoY to ₹578.02 Cr compared to ₹471.43 Cr in 9M FY25.Successful USFDA inspection in Feb 2026 with zero Form 483 observations reinforces regulatory excellence.Q3 FY26 PAT surged 76.7% QoQ to ₹13.45 Cr from ₹7.61 Cr in the preceding quarter.Total manufacturing capacity enhanced to 2,400 MTPA in 2025 from 2,200 MTPA.EBITDA for Q3 FY26 stood at ₹20.91 Cr, representing 10.60% of sales compared to 6.92% in Q2 FY26.
👀 கவனிக்க வேண்டியவை
The zero USFDA observations and strong sequential margin recovery are significant positive triggers for the stock. Investors should monitor the company's ability to sustain these margins as it utilizes its newly expanded 2,400 MTPA capacity.
Anuh Pharma Q3 FY26 PAT Jumps 30% YoY to ₹13.45 Cr; Revenue Up 23.6%
Anuh Pharma reported a strong quarterly performance for the period ended December 31, 2025, with revenue from operations growing 23.6% YoY to ₹197.18 crore. Net profit for the quarter rose significantly by 30% YoY to ₹13.45 crore, aided by improved EBITDA margins which stood at 10.60%. On a sequential basis, the profit growth was even more pronounced, surging 76.7% compared to the preceding quarter (Q2 FY26). While the nine-month revenue is up 23%, the cumulative net profit remains lower than the previous year due to higher input costs incurred in the first half of the fiscal year.
முக்கிய அம்சங்கள்
Revenue from operations increased by 23.6% YoY to ₹197.18 crore in Q3 FY26.Net Profit (PAT) grew by 30% YoY to ₹13.45 crore, with a sharp 76.7% sequential recovery from Q2 FY26.EBITDA margins improved to 10.60% in Q3 FY26 compared to 9.86% in the same quarter last year.Earnings Per Share (EPS) for the quarter stood at ₹1.34, adjusted for the 1:1 bonus share issuance in July 2025.The company recognized a one-time incremental obligation of ₹48.31 lakhs related to the implementation of New Labour Codes.
👀 கவனிக்க வேண்டியவை
The strong quarterly recovery in margins and bottom-line growth indicates a positive shift in operational efficiency. Investors should monitor the sustainability of these margins in the upcoming quarter to confirm a full turnaround from the high-cost environment seen earlier in the year.
Anuh Pharma Receives EDQM Approval (CEP) for Sulfadimethoxine API
Anuh Pharma Limited has successfully obtained the Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its product, Sulfadimethoxine. This regulatory milestone signifies that the company's Active Pharmaceutical Ingredient (API) meets the stringent quality standards required for the European market. The approval is expected to facilitate expanded access to regulated international markets and enhance the company's export potential. This development strengthens Anuh Pharma's position as a reliable supplier of high-quality APIs globally.
முக்கிய அம்சங்கள்
Received Certificate of Suitability (CEP) from the EDQM for Sulfadimethoxine.Approval validates compliance with stringent European regulatory and quality standards.Enables the company to expand its market reach into highly regulated pharmaceutical regions.Expected to improve supply security and reliability for global pharmaceutical customers.Strengthens the company's API portfolio for international trade.
👀 கவனிக்க வேண்டியவை
Investors should monitor the potential increase in export revenue from the European market in future quarters. This regulatory win is a positive indicator of the company's manufacturing quality and long-term growth prospects in regulated markets.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
